Institution Directory

Clinical trials at UT Southwestern Medical Center

Sites in Dallas, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1260

Shown on this page

Current sort

Live official records

Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Questionnaire Administration; Drug · Procedure · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 70 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 326
States / cities: Fayetteville, Arkansas • Fort Smith, Arkansas • Rogers, Arkansas + 256 more

Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions: Cytoreductive Nephrectomy, Active Comparator; Procedure · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2033
U.S. locations: 387
States / cities: Birmingham, Alabama • Gilbert, Arizona • Kingman, Arizona + 262 more

Conditions: Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Advanced, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic/Advanced Renal Cell Carcinoma
Interventions: PF-08634404, Ipilimumab, Axitinib, Casdatifan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 160
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 101 more

Conditions: Homocystinuria
Interventions: Pegtibatinase, Placebo; Drug · Other
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more

Conditions: Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell Marginal Zone, Waldenstrom Macroglobulinemia, Lymphoma, Mantle Cell
Interventions: LY4152199 - IV; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 23
States / cities: Duarte, California • Aurora, Colorado • Denver, Colorado + 17 more

Conditions: Colon Adenocarcinoma, Rectal Adenocarcinoma
Interventions: Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium, 5-Fluorouracil, Cetuximab, Bevacizumab, Bevacizumab biosimilar; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 48
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 43 more

Conditions: Brain Neoplasms, Adult, Malignant
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cystic Fibrosis, Parenthood Status
Interventions: Parenthood; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 18
States / cities: Birmingham, Alabama • Denver, Colorado • Evanston, Illinois + 14 more

Conditions: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Interventions: Vepugratinib, Placebo, EV, Pembrolizumab; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 64
States / cities: Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more

Conditions: Patent Ductus Arteriosus (PDA)
Interventions: Bloom Micro Occluder System; Device
Lead sponsor: Merit Medical Systems, Inc.; Industry
Eligibility: 5 Days and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Sacramento, California • San Diego, California • Hollywood, Florida + 6 more

Conditions: Liver Fibroses, Cirrhosis
Interventions: Atorvastatin 20mg, Placebo; Drug
Lead sponsor: Raymond Chung; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Renal Cell Carcinoma
Interventions: Tivozanib, Nivolumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Irvine, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

About this UT Southwestern Medical Center institution page

What this page lists: ClinicalTrials.gov records that list UT Southwestern Medical Center in Dallas, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UT Southwestern Medical Center

Filter and sort this campus

Live official records

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Stereotactic Radiosurgery (SRS) Dose-Escalation Study for Brain Metastasis

Health Outcomes of Parents With Cystic Fibrosis-Aim 2

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

PREEMIE: Study for Treatment of PDA in Premature Infants

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

About this UT Southwestern Medical Center institution page